Efficacy Shown for New Melanoma Therapeutic Vaccine
Patients who received the vaccine plus Keytruda were 49 percent less likely to die or have their cancer return after three years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.